This site is intended for healthcare professionals
CDK4/6 inhibitors in breast cancer


Read time: 160 mins
Last updated:26th Jul 2021
Published:30th May 2020
Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?

Abemaciclib, palbociclib and ribociclib are three EMA and FDA approved CDK4/6 inhibitors for the treatment of hormone receptor positive/human epidermal growth factor 2 negative (HR+/HER2-) metastatic breast cancer1–6. This learning zone aims to introduce the clinical trial data that will help you to select the best CDK4/6 inhibitor for your patient. We highlight how differences in safety and toxicity between the three treatments may influence your decision. We also discuss the evidence for each inhibitor in distinct patient subgroups including postmenopausal women, premenopausal women and the elderly.

We also point out how the data differ for each CDK4/6 inhibitor according to disease characteristics including endocrine sensitivity, type of metastasis, central nervous system involvement, and pretreatment.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest